Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SARS-CoV-2 Vaccine IN-B009 in Healthy Adults
NCT05113849Phase 1Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Sep 2021
- Primary completion
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of IN-B009 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by HK inno.N Corporation. Primary endpoints: Occurrence rate of Immediate Adverse Reaction (IAR), Occurrence rate of solicited local and systemic AE and 9 more. Status: unknown.
02
Drugs
IN-B009
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05113849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113849.